RhumbLine Advisers
IMDX

RhumbLine Advisers’s Insight Molecular Diagnostics IMDX Stock Holding History

RhumbLine Advisers’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-66
Closed -$204 – 4258
2023
Q4 		$164 Hold
66
– – ﹤0.01% 4240
2023
Q3 		$216 Hold
66
– – ﹤0.01% 4265
2023
Q2 		$304 Buy
+66
New +$332 ﹤0.01% 4339
2022
Q2 		– Sell
-3,018
Closed -$90K – 3193
2022
Q1 		$90K Buy
3,018
+143
+5% +$4.57K ﹤0.01% 2905
2021
Q4 		$125K Sell
2,875
-274
-9% -$15.8K ﹤0.01% 2913
2021
Q3 		$224K Sell
3,149
-207
-6% -$19K ﹤0.01% 2868
2021
Q2 		$385K Buy
3,356
+805
+32% +$78.6K ﹤0.01% 2677
2021
Q1 		$265K Buy
2,551
+197
+8% +$18.7K ﹤0.01% 2744
2020
Q4 		$112K Buy
2,354
+652
+38% +$23.9K ﹤0.01% 2957
2020
Q3 		$47K Sell
1,702
-153
-8% -$4.39K ﹤0.01% 2952
2020
Q2 		$71K Buy
1,855
+963
+108% +$49.7K ﹤0.01% 3005
2020
Q1 		$44K Hold
892
– – ﹤0.01% 2871
2019
Q4 		$40K Hold
892
– – ﹤0.01% 2920
2019
Q3 		$37K Sell
892
-10
-1% -$393 ﹤0.01% 2937
2019
Q2 		$45K Buy
+902
New +$75K ﹤0.01% 2958

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RhumbLine Advisers's IMDX Position: Q1 2024 in Review

RhumbLine Advisers sold out of Insight Molecular Diagnostics (IMDX) in Q1 2024, closing a stake of 66 shares — an estimated $204 sold.

RhumbLine Advisers first reported a position in IMDX in Q2 2019 and held it in 15 quarters. The position peaked at $385K in Q2 2021. 25 funds tracked by Wall St. Rank hold IMDX as of Q1 2024.

  • RhumbLine Advisers reported no remaining Insight Molecular Diagnostics position as of Q1 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 66 Insight Molecular Diagnostics shares in Q1 2024, an estimated $204.
  • RhumbLine Advisers first reported a position in Insight Molecular Diagnostics in Q2 2019 and held it in 15 quarters.
  • RhumbLine Advisers's Insight Molecular Diagnostics position peaked at $385K in Q2 2021.
  • 25 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2024.

Based on RhumbLine Advisers's 13F filing for Q1 2024, filed 9 May 2024.